Laquinimod Reduces Signs of Inflammation, Brain Atrophy in Huntington’s, Data Show
Laquinimod, an experimental immunomodulatory therapy developed by Active Biotech and Teva Pharmaceuticals, reduced signs of inflammation and brain atrophy (shrinkage) in patients with Huntington’s disease, data from an exploratory analysis of a Phase 2 trial show. The new data were presented by Active Biotech in three posters…